FDA Issues Warning For BMS Hepatitis B Drug Entecavir

Main Category: HIV / AIDS
Also Included In: Liver Disease / Hepatitis
Article Date: 22 Aug 2007 - 10:00 PDT

email to a friend   printer friendly   opinions  

FDA on Thursday issued a warning that Bristol-Myers Squibb's hepatitis B drug entecavir might increase the likelihood of developing resistance to antiretroviral drugs among people coinfected with HIV, Reuters reports. The agency also added a black box warning to the drug's label. BMS -- which manufactures and sells entecavir under the brand name Baraclude -- in a letter to physicians wrote that people coinfected with hepatitis B and HIV should not take entecavir unless they are taking standard antiretrovirals. According to the warning, drug resistance can develop if a person is not being treated for HIV. The warning also said that HIV testing should be offered to any person who considers taking entecavir (Reuters, 8/16). There are more than four million people worldwide living with both hepatitis B and HIV who need treatment for hepatitis B but have not started antiretrovirals (Kaiser Daily HIV/AIDS Report, 3/2).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations